智通财经APP获悉，德琪医药-B(06996)早盘重挫逾30%，截至发稿，跌29.23%，报2.3港元，成交额856.09万港元。
消息面上，德琪医药此前发布年度业绩，该集团取得收入9195万元人民币，同比增加36.62%；研发开支2.59亿元，同比减少36.18%；年内亏损3.19亿元，同比减少45.07%；经调整年内亏损3.05亿元，同比减少42.95%。据悉，2024年塞利尼索销售额同比增长37%至9195万元人民币，其中海外市场增长95%。
中信建投认为，关税政策冲击下，对医药产业链的影响较为复杂，并且可能仍然存在变数。公司此前宣布，印度尼西亚食品药品监督管理局（BPOM）已批准希维奥的新药上市申请（NDA）。据悉，希维奥是全球首个全新机制的口服选择性XPO1抑制剂，已在亚太市场的10个国家和地区获批用于治疗多项适应症，并在其中5个市场实现医保收录。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.